What Is NAD+ and How Do NAD+ Precursors Work? NMN and NR Explained

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell of your body that is essential for energy metabolism, DNA repair, and cellular signaling. NAD+ levels decline approximately 50% between ages 40 and 60, and this decline is associated with aging-related metabolic dysfunction. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursor molecules that your body converts into NAD+. Both have shown the ability to raise NAD+ levels in human clinical trials. The key distinction: NMN converts to NAD+ in one enzymatic step, while NR requires two steps — but whether this translates into a meaningful clinical difference is still an open question.

NAD+ is not a vitamin, a supplement category, or a marketing buzzword — it is one of the most fundamental molecules in cellular biology. It participates in over 500 enzymatic reactions, making it involved in more metabolic processes than almost any other molecule in the body. Its most critical role is in energy production. NAD+ shuttles electrons in the mitochondria during oxidative phosphorylation — the process that generates ATP, your cells' energy currency. Without adequate NAD+, mitochondrial efficiency drops. Cells produce less energy. Tissues that are metabolically demanding — brain, heart, muscle, liver — feel the deficit first. NAD+ is also the essential substrate for sirtuins, a family of seven enzymes (SIRT1-7) that regulate gene expression, inflammation, stress resistance, and mitochondrial biogenesis. Sirtuins cannot function without NAD+ — they literally consume it during every catalytic cycle. David Sinclair's research at Harvard (published in Cell, 2013) demonstrated that declining NAD+ levels lead to reduced sirtuin activity, which contributes to the aging phenotype in mice. A third critical function: NAD+ is consumed by PARP enzymes (poly ADP-ribose polymerases) during DNA repair. When DNA damage accumulates — from oxidative stress, UV radiation, or normal metabolic byproducts — PARPs use NAD+ to repair it. As you age and DNA damage accumulates, PARPs consume more NAD+, leaving less available for energy production and sirtuin activity. This creates a competition for a shrinking pool — which is the core rationale for NAD+ supplementation research.

NAD+ levels do not decline because you stop making it. Your body continues to synthesize NAD+ through multiple pathways throughout life. The decline happens because consumption increases faster than production can keep up. Three factors drive the increased consumption. First, chronic low-grade inflammation (sometimes called inflammaging) activates an enzyme called CD38, which is one of the largest NAD+ consumers in the body. CD38 activity increases dramatically with age — a 2016 study in Cell Metabolism showed that CD38 is responsible for the majority of age-related NAD+ decline in mice, not reduced synthesis. This finding shifted the field's understanding: the problem is not that old bodies cannot make NAD+, it is that they burn through it faster. Second, accumulated DNA damage increases PARP activity, consuming more NAD+ for repair. Third, senescent cells (damaged cells that stop dividing but refuse to die) secrete inflammatory signals that further activate CD38 and deplete NAD+ in surrounding tissue. The practical result: by age 50-60, most people have roughly half the NAD+ levels they had at age 20. This correlates with — though does not necessarily cause — the metabolic changes associated with aging: reduced mitochondrial function, increased inflammation, impaired DNA repair, and declining cellular stress resistance. The causation question is exactly what NAD+ precursor research is trying to answer.

Your body can make NAD+ through several pathways, but the salvage pathway — recycling nicotinamide (a form of vitamin B3) back into NAD+ — handles the majority of day-to-day NAD+ production. Both NMN and NR feed into this salvage pathway at different entry points. NR (nicotinamide riboside) enters the cell and is phosphorylated by the enzyme NRK (nicotinamide riboside kinase) to become NMN. Then NMN is converted to NAD+ by the enzyme NMNAT. Two enzymatic steps total. NMN (nicotinamide mononucleotide) is one step ahead — it only needs the NMNAT conversion to become NAD+. One step. However, NMN is a larger molecule than NR and its ability to cross cell membranes directly was debated for years. A 2019 discovery identified the Slc12a8 transporter that moves NMN into cells in the small intestine, partially resolving this question. NR, being smaller, enters cells more readily through equilibrative nucleoside transporters. In human trials: NR has been studied longer. The 2018 CHROMADIET trial and a 2017 Martens et al. study showed NR at 1,000 mg/day raised blood NAD+ levels by 40-60% in healthy adults. NMN human data is more recent — a 2022 study (Yi et al., Science) showed 1,250 mg NMN daily for 2 weeks raised blood NAD+ by approximately 38% in healthy men. Both work. The question of which raises intracellular NAD+ more effectively in specific tissues is still unresolved. Dosed supports protocol tracking for NAD+ precursor supplementation including dose logging, timing schedules, and the ability to note subjective effects over time for personal record-keeping.

Here is where you need to separate the science from the marketing. The animal data for NAD+ precursors is genuinely impressive. Mice given NMN or NR show improved mitochondrial function, better glucose tolerance, enhanced exercise capacity, reduced inflammation, and in some studies, extended healthspan. Sinclair's 2013 Cell paper showed that old mice given NMN for one week had mitochondrial function indistinguishable from young mice — a striking result that launched the field. The human data is more modest. Clinical trials have confirmed that NMN and NR raise blood NAD+ levels in humans. But raising NAD+ levels is a biomarker change, not a clinical outcome. The question that matters — do higher NAD+ levels translate into measurable health benefits in humans? — has weaker evidence. Some positive signals: a 2022 randomized trial of NMN in older adults showed modest improvements in walking speed and grip strength. A 2023 trial of NR showed improved mitochondrial membrane potential in peripheral blood cells. Several small trials report improved insulin sensitivity. But none of these are large, long-term, replicated results. The effect sizes are small, the sample sizes are modest (typically 30-80 participants), and the durations are short (8-12 weeks). The honest assessment: NAD+ precursors are one of the more promising interventions in aging research, with a strong mechanistic rationale and encouraging animal data. The human evidence supports the biochemistry (levels do rise) but has not yet demonstrated transformative clinical benefits. The research is still early. Anyone claiming NMN or NR is proven to reverse aging in humans is outrunning the data. This content is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting any supplementation protocol.